174 related articles for article (PubMed ID: 20498405)
41. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W;
J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954
[TBL] [Abstract][Full Text] [Related]
42. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
Pedrazzoli P; Da Prada GA; Giorgiani G; Schiavo R; Zambelli A; Giraldi E; Landonio G; Locatelli F; Siena S; Della Cuna GR
Cancer; 2002 May; 94(9):2409-15. PubMed ID: 12015766
[TBL] [Abstract][Full Text] [Related]
43. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Quigley J; Chen YH; Mahmud N; Hurter E; Beri R; Rondelli D
Bone Marrow Transplant; 2008 Jun; 41(11):935-40. PubMed ID: 18264144
[TBL] [Abstract][Full Text] [Related]
44. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
[TBL] [Abstract][Full Text] [Related]
45. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
46. Total body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies.
Petropoulos D; Worth LL; Mullen CA; Madden R; Mahajan A; Choroszy M; Ha CS; Champlin RC; Chan KW
Bone Marrow Transplant; 2006 Mar; 37(5):463-7. PubMed ID: 16435013
[TBL] [Abstract][Full Text] [Related]
47. Transplantation of allogeneic CD34-selected stem cells after fludarabine-based conditioning regimen for children with mucopolysaccharidosis 1H (M. Hurler).
Grigull L; Beilken A; Schrappe M; Das A; Luecke T; Sander A; Stanulla M; Rehe K; Sauer M; Schmid H; Welte K; Lukacs Z; Gal A; Sykora KW
Bone Marrow Transplant; 2005 Feb; 35(3):265-9. PubMed ID: 15580280
[TBL] [Abstract][Full Text] [Related]
48. Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial.
Falda M; Busca A; Baldi I; Mordini N; Bruno B; Allione B; Rambaldi A; Morello E; Narni F; Santarone S; Locatelli F; Bacigalupo A;
Am J Hematol; 2007 Oct; 82(10):863-6. PubMed ID: 17616972
[TBL] [Abstract][Full Text] [Related]
49. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.
Rizzieri DA; Koh LP; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Smith C; Gong JZ; Lagoo A; Niedzwiecki D; Dowell JM; Waters-Pick B; Liu C; Marshall D; Vredenburgh JJ; Gockerman J; Decastro C; Moore J; Chao NJ
J Clin Oncol; 2007 Feb; 25(6):690-7. PubMed ID: 17228020
[TBL] [Abstract][Full Text] [Related]
50. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Chen HY; Mahmud N; Quigley J; Hoffman R; Jessop E; Beri R; Rondelli D
Bone Marrow Transplant; 2006 Oct; 38(7):477-82. PubMed ID: 16980995
[TBL] [Abstract][Full Text] [Related]
51. Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality.
Hartwig UF; Winkelmann N; Wehler T; Kreiter S; Schneider PM; Meyer RG; Ullmann AJ; Huber C; Kolbe K; Herr W
Ann Hematol; 2005 May; 84(5):331-8. PubMed ID: 15726363
[TBL] [Abstract][Full Text] [Related]
52. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.
Iravani M; Evazi MR; Mousavi SA; Shamshiri AR; Tavakoli M; Ashouri A; Samiee S; Chahardovali B; Alimoghaddam K; Ghaffari SH; Ghavamzadeh A
Bone Marrow Transplant; 2007 Jul; 40(2):105-10. PubMed ID: 17468775
[TBL] [Abstract][Full Text] [Related]
53. Low incidence and severity of oral mucositis in allogeneic stem cell transplantation after conditioning with treosulfan and fludarabine.
Heli U; Eeva J; Anne N; Tapani R; Liisa V
Eur J Haematol; 2012 Jan; 88(1):87-8. PubMed ID: 22103782
[No Abstract] [Full Text] [Related]
54. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.
Geddes M; Kangarloo SB; Naveed F; Quinlan D; Chaudhry MA; Stewart D; Savoie ML; Bahlis NJ; Brown C; Storek J; Andersson BS; Russell JA
Biol Blood Marrow Transplant; 2008 Feb; 14(2):220-8. PubMed ID: 18215782
[TBL] [Abstract][Full Text] [Related]
55. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
Brown JR; Kim HT; Li S; Stephans K; Fisher DC; Cutler C; Ho V; Lee SJ; Milford EL; Ritz J; Antin JH; Soiffer RJ; Gribben JG; Alyea EP
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1056-64. PubMed ID: 17084369
[TBL] [Abstract][Full Text] [Related]
56. Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients.
Baronciani D; Rambaldi A; Iori AP; Di Bartolomeo P; Pilo F; Pettinau M; Depau C; Mico C; Santarone S; Angelucci E
Am J Hematol; 2008 Sep; 83(9):717-20. PubMed ID: 18626885
[TBL] [Abstract][Full Text] [Related]
57. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen.
Morecki S; Gelfand Y; Nagler A; Or R; Naparstek E; Varadi G; Engelhard D; Akerstein A; Slavin S
Bone Marrow Transplant; 2001 Aug; 28(3):243-9. PubMed ID: 11535991
[TBL] [Abstract][Full Text] [Related]
58. Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.
Nemecek ER; Guthrie KA; Sorror ML; Wood BL; Doney KC; Hilger RA; Scott BL; Kovacsovics TJ; Maziarz RT; Woolfrey AE; Bedalov A; Sanders JE; Pagel JM; Sickle EJ; Witherspoon R; Flowers ME; Appelbaum FR; Deeg HJ
Biol Blood Marrow Transplant; 2011 Mar; 17(3):341-50. PubMed ID: 20685259
[TBL] [Abstract][Full Text] [Related]
59. Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes.
Shimoni A; Hardan I; Shem-Tov N; Rand A; Yerushalmi R; Nagler A
Leuk Lymphoma; 2007 Dec; 48(12):2352-9. PubMed ID: 18067010
[TBL] [Abstract][Full Text] [Related]
60. Treosulfan-fludarabine-thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho-proliferative disease. A single centre study.
Baronciani D; Depau C; Targhetta C; Derudas D; Culurgioni F; Tandurella I; Latte G; Palmas A; Angelucci E
Hematol Oncol; 2016 Mar; 34(1):17-21. PubMed ID: 25626861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
